Nascent Pharma Holdings(NASC)
$0.010.00 (0.00%)
NASC
Nascent Pharma Holdings financials statements
$0.01
At close:0.00 (0.00%)
Want to see NASC full AI Analyst Report?
Nascent Pharma Holdings (NASC) Ratios
28 Followers
Nascent Pharma Holdings Ratios
NASC's free cash flow for Q3 2024 was $9.10K. For the 2024 fiscal year, NASC's free cash flow was increased by $0.00 and operating cash flow was $9.10K. See a summary of the company’s cash flow.
| Ratios | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Mar 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.02 | 0.48 | 0.70 | 0.70 | 1.27 |
| Quick Ratio | 0.02 | 0.34 | 0.54 | 0.43 | 1.11 |
| Cash Ratio | 0.00 | 0.00 | 0.01 | 0.05 | 0.21 |
| Solvency Ratio | -0.76 | -0.75 | -1.05 | -1.07 | -3.32 |
| Operating Cash Flow Ratio | -0.02 | -0.12 | -0.32 | -0.77 | -0.88 |
| Short-Term Operating Cash Flow Coverage | -0.03 | -0.15 | -0.48 | -1.44 | -1.07 |
| Net Current Asset Value | $ -12.74M | $ -5.75M | $ -4.16M | $ -4.20M | $ 381.26K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 27.72 | 0.91 | 0.60 | 0.44 | 0.53 |
| Debt-to-Equity Ratio | -0.65 | -9.16 | 3.46 | 1.30 | 1.41 |
| Debt-to-Capital Ratio | -1.88 | 1.12 | 0.78 | 0.56 | 0.59 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.14 | 0.20 | 0.12 |
| Financial Leverage Ratio | -0.02 | -10.11 | 5.77 | 2.93 | 2.65 |
| Debt Service Coverage Ratio | -0.76 | -0.51 | -1.38 | -1.33 | -2.59 |
| Interest Coverage Ratio | -2.68 | -2.98 | -15.71 | -4.88 | -8.06 |
| Debt to Market Cap | 3.99 | 26.76 | 1.87 | 9.64 | 13.20 |
| Interest Debt Per Share | 0.17 | 0.93 | 2.87 | 6.99 | 12.80 |
| Net Debt to EBITDA | -1.08 | -1.57 | -0.74 | -0.72 | -0.23 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 16.64% | 39.11% | 64.99% | 83.74% |
| EBIT Margin | 0.00% | -334.78% | -209.73% | -218.65% | -464.47% |
| EBITDA Margin | 0.00% | -269.84% | -188.26% | -206.87% | -418.66% |
| Operating Profit Margin | 0.00% | -347.28% | -211.92% | -222.99% | -440.83% |
| Pretax Profit Margin | 0.00% | -451.25% | -223.22% | -264.31% | -519.14% |
| Net Profit Margin | 0.00% | -451.70% | -223.23% | -264.33% | -519.33% |
| Continuous Operations Profit Margin | 0.00% | -451.70% | -223.23% | -264.33% | -519.33% |
| Net Income Per EBT | 104.37% | 100.10% | 100.01% | 100.01% | 100.04% |
| EBT Per EBIT | 205.45% | 129.94% | 105.33% | 118.53% | 117.76% |
| Return on Assets (ROA) | -3406.45% | -96.16% | -95.92% | -73.87% | -226.99% |
| Return on Equity (ROE) | 80.19% | 971.83% | -553.17% | -216.56% | -601.54% |
| Return on Capital Employed (ROCE) | 37.40% | 747.17% | -451.79% | -146.41% | -446.90% |
| Return on Invested Capital (ROIC) | 107.66% | -91.53% | -117.73% | -79.56% | -211.86% |
| Return on Tangible Assets | -3406.45% | -97.07% | -96.58% | -75.56% | -266.41% |
| Earnings Yield | -490.35% | -2918.56% | -321.56% | -1811.98% | -5796.74% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.58 | 1.02 | 1.26 | 0.85 |
| Payables Turnover | 0.19 | 0.92 | 1.30 | 1.39 | 1.81 |
| Inventory Turnover | 0.00 | 1.11 | 2.01 | 0.63 | 0.81 |
| Fixed Asset Turnover | 0.00 | 0.49 | 1.02 | 0.50 | 1.62 |
| Asset Turnover | 0.00 | 0.21 | 0.43 | 0.28 | 0.44 |
| Working Capital Turnover Ratio | 0.00 | -0.46 | -2.05 | -4.15 | 0.98 |
| Cash Conversion Cycle | -1964.00 | 564.26 | 259.49 | 603.94 | 679.39 |
| Days of Sales Outstanding | 0.00 | 630.42 | 359.58 | 289.12 | 428.26 |
| Days of Inventory Outstanding | 0.00 | 328.95 | 181.47 | 578.26 | 452.81 |
| Days of Payables Outstanding | 1964.00 | 395.10 | 281.55 | 263.44 | 201.68 |
| Operating Cycle | 0.00 | 959.37 | 541.05 | 867.38 | 881.06 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.10 | -1.11 | -5.45 | -8.26 |
| Free Cash Flow Per Share | -0.00 | -0.10 | -1.11 | -5.98 | -8.48 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -86.97 | 0.00 | -10.22 | -38.77 |
| Capital Expenditure Coverage Ratio | 0.00 | -86.97 | 0.00 | -10.22 | -38.77 |
| Operating Cash Flow Coverage Ratio | -0.03 | -0.14 | -0.42 | -1.01 | -0.94 |
| Operating Cash Flow to Sales Ratio | 0.00 | -0.61 | -0.59 | -1.59 | -1.14 |
| Free Cash Flow Yield | -10.65% | -395.49% | -85.05% | -1196.99% | -1303.98% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.21 | -0.03 | -0.31 | -0.06 | -0.02 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.15 | 0.69 | 0.15 | 0.09 |
| Price-to-Book (P/B) Ratio | -0.16 | -0.33 | 1.72 | 0.12 | 0.10 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -9.39 | -0.25 | -1.18 | -0.08 | -0.08 |
| Price-to-Operating Cash Flow Ratio | -9.39 | -0.26 | -1.18 | -0.09 | -0.08 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Enterprise Value Multiple | -1.36 | -1.63 | -1.10 | -0.79 | -0.25 |
| Enterprise Value | 10.38M | 9.48M | 13.90M | 7.51M | 1.78M |
| EV to EBITDA | -1.36 | -1.63 | -1.10 | -0.79 | -0.25 |
| EV to Sales | 0.00 | 4.40 | 2.08 | 1.63 | 1.04 |
| EV to Free Cash Flow | -46.83 | -7.19 | -3.52 | -0.93 | -0.89 |
| EV to Operating Cash Flow | -46.83 | -7.27 | -3.52 | -1.03 | -0.91 |
| Tangible Book Value Per Share | -0.22 | -0.09 | 0.73 | 3.91 | 3.81 |
| Shareholders’ Equity Per Share | -0.22 | -0.08 | 0.76 | 4.18 | 6.26 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.00 | 0.17 | 1.87 | 3.43 | 7.26 |
| Net Income Per Share | -0.17 | -0.77 | -4.18 | -9.06 | -37.68 |
| Tax Burden | 1.04 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.22 | 1.35 | 1.06 | 1.21 | 1.12 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 |
| SG&A to Revenue | 0.00 | 2.20 | 2.03 | 2.09 | 2.70 |
| Stock-Based Compensation to Revenue | 0.00 | 0.67 | 0.76 | 0.52 | 1.51 |
| Income Quality | 0.02 | 0.13 | 0.26 | 0.60 | 0.34 |
Currency in USD

